Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?

Much promise and encouragement has been linked to the treatment of patients with advanced NSCLC harboring EGFR mutations. The first generation EGFR TKIs (e.g., erlotinib/gefitinib) gave promise as single agent therapy in the first-line setting (1). The second generation EGFR TKI with covalent irreversible binding to the receptor and with the potential to target heterodimers of the Erb-B receptors gave further promise regarding response, progressionfree survival and overall survival, particularly in patients with exon 19 deletions (2-4).